Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists

A compound of the formula ##STR37## or pharmaceutically acceptable salts thereof, wherein R.sub.2 is selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyl;

• R.sub.3 is selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyloxycarbonyl;
• R.sub.4 is selected from the group consisting of C.sub.1 -C.sub.6 alkyl, phenyl C.sub.2 -C.sub.6 alkenyl, phenyl C.sub.2 -C.sub.6 alkynyl, aryl, and aryl substituted with one or more substituents selected from the group consisting of nitro and C.sub.1 -C.sub.6 alkyloxy;
• R.sub.5 is selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 alkyloxycarbonyl, and aryl C.sub.1 -C.sub.6 alkyloxy carbonyl;
• R.sub.6 is selected from the group consisting of hydrogen, aryl, and C.sub.1 -C.sub.6 alkyl;
• with the proviso that when R.sub.2 .dbd.R.sub.3 .dbd.R.sub.5 .dbd.R.sub.6 .dbd.hydrogen, R.sub.4 is not alkyl.

A compound of the formula ##STR38## wherein R.sub.1 and R.sub.3 are selected from the group consisting of hydrogen, hydroxy, C.sub.1 -C.sub.6 alkyloxy, and C.sub.1 -C.sub.6 alkylcarbonyloxy;

• R.sub.2 is selected from the group consisting of hydrogen, hydroxy, C.sub.1 -C.sub.6 alkyloxy, C.sub.1 -C.sub.6 alkylcarbonyloxy, and C.sub.2 -C.sub.6 alkenyloxy, said alkenyloxy together with the carbon atom of the phenyl ring forming an oxygen heterocycle;
• and R.sub.4 is selected from the group consisting of phenyl, styryl, phenylbutadienyl, phenylacetylenyl, and --CH.dbd.N-phenyl, and substituted phenyl, styryl, phenylacetylenyl, and phenylbutadienyl, wherein the phenyl ring is substituted with 1 to 5 C.sub.1 -C.sub.6 alkyloxy groups;
• with the provisos that when R.sub.3 is hydrogen, R.sub.1 and R.sub.2 are neither hydroxy nor alkyloxy;
• when R.sub.1, R.sub.2, and R.sub.3 are hydrogen, R.sub.4 is neither phenyl nor alkyloxyphenyl;
• when R.sub.3 is hydrogen and R.sub.4 is phenyl, neither R.sub.1 nor R.sub.2 is alkylcarbonyloxy;
• and when R.sub.3 is hydroxy or alkyloxy, R.sub.1 and R.sub.2 are not dihydroxy.

A method of treating a mammal comprising selectively blocking one or more adenosine receptors of said mammal by administering to said mammal at least one compound of the formula ##STR40## wherein R.sub.1 and R.sub.3 are selected from the group consisting of hydrogen, hydroxy, C.sub.1 -C.sub.6 alkyloxy, and C.sub.1 -C.sub.6 alkylcarbonyloxy;

• R.sub.2 is selected from the group consisting of hydrogen, hydroxy, C.sub.1 -C.sub.6 alkyloxy, C.sub.1 -C.sub.6 alkylcarbonyloxy, and C.sub.2 -C.sub.6 alkenyloxy, said alkenyloxy together with the carbon atom of the phenyl ring forming an oxygen heterocycle;
• R.sub.4 is selected from the group consisting of phenyl, styryl, phenylbutadienyl, phenylacetylenyl, and --CH.dbd.N-phenyl, and substituted phenyl, styryl, phenylacetylenyl, and phenylbutadienyl, wherein the phenyl ring is substituted with 1 to 5 C.sub.1 -C.sub.6 alkyloxy groups;
• with the provisos that when R.sub.3 is hydrogen, R.sub.1 and R.sub.2 are neither hydroxy nor alkyloxy;
• when R.sub.1, R.sub.2, and R.sub.3 are hydrogen, R.sub.4 is neither phenyl nor alkyloxyphenyl;
• and when R.sub.3 is hydrogen and R.sub.4 is phenyl, neither R.sub.1 nor R.sub.2 is alkylcarbonyloxy.